Riebel V: Difference between revisions
From Bioblast
No edit summary |
Beno Marija (talk | contribs) Β |
||
(2 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{Person | {{Person | ||
|lastname=Riebel | |||
|firstname=Virginie | |firstname=Virginie | ||
| | |institution=Novartis Pharma AG, Werk Klybeck | ||
|area code=CH-4002 | |||
|city=Basel | |||
|country=Switzerland | |||
}} | }} | ||
{{Labelingperson}} | |||
==Participated at== | |||
::::*[[IOC39|IOC39 Schroecken AT]] |
Latest revision as of 16:25, 12 February 2018
Name | Riebel Virginie, |
---|---|
Institution | Novartis Pharma AG, Werk Klybeck |
Address | , CH-4002 |
City | Basel |
State/Province | |
Country | Switzerland |
[email protected] | |
Weblink | |
O2k-Network Lab | CH Basel Uteng M |
Labels:
Publications
Published | Reference | |
---|---|---|
Brecht 2016 Toxicol In Vitro | 2016 | Brecht K, Riebel V, Couttet P, Paech F, Wolf A, Chibout SD, Pognan F, KrΓ€henbΓΌhl S, Uteng M (2016) Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin. Toxicol In Vitro 40:55-65. |